Galbanic acid decreases androgen receptor abundance and signaling and induces G 1 arrest in prostate cancer cells

International Journal of Cancer

Volumn 130, Issue 1, 2012, Pages 200-212

  Zhang, Yong ^a,b,e   Kim, Kwan Hyun ^a,c   Zhang, Wei ^d   Guo, Yinglu ^b   Kim, Sung Hoon ^a   Lü, Junxuan ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PEKING UNIVERSITY   (China)

^c Kyung Hee University   (South Korea)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

^e TTUHSC School of Medicine   (United States)

Author keywords

androgen receptor; G 1 arrest; galbanic acid; prostate cancer; proteasomal degradation

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CASPASE; CASPASE INHIBITOR; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; GALBANIC ACID;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL NUCLEUS; CELL STRAIN DU145; CELL STRAIN LNCAP; CELL STRAIN PC 3; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; FENNEL; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DOCKING; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN METABOLISM; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL CYCLE PROTEINS; CELL PROLIFERATION; COUMARINS; CYCLIN D; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; E2F TRANSCRIPTION FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FERULA; FLOW CYTOMETRY; G1 PHASE; HUMANS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; MALE; MODELS, MOLECULAR; NITRILES; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOSYL COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 80255123491     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25993     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ,. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
2. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308. (Pubitemid 38501396)
3. Kung HJ, Evans CP,. Oncogenic activation of androgen receptor. Urol Oncol 2009; 27: 48-52.
4. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-61. (Pubitemid 46211563)
5. Petrylak DP,. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 2005; 65: 3-7; discussion 8.
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9. (Pubitemid 38524696)
7. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z,. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res 2007; 35: 2767-76. (Pubitemid 47073687)
8. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8.
9. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90.
10. 1 and induction of caspase-dependent apoptosis. Phytomedicine 2008; 15: 103-11.
11. Saleem M, Alam A, Sultana S,. Asafoetida inhibits early events of carcinogenesis: a chemopreventive study. Life Sci 2001; 68: 1913-21. (Pubitemid 32245615)
12. Unnikrishnan MC, Kuttan R,. Tumour reducing and anticarcinogenic activity of selected spices. Cancer Lett 1990; 51: 85-9. (Pubitemid 20147621)
13. Bedniak AE, Pershin GN, Milovanova SN,. [Antibacterial activity of galbanic acid and of its conversion products]. Farmatsiia 1967; 16: 45-9.
14. Mansurov MM, Martirosov MS,. [The action of the sodium salt of galbanic acid in experimental erythrocyte hyperaggregation]. Farmakol Toksikol 1990; 53: 51-3. (Pubitemid 20047287)
15. Syrov VN, Khushbaktova ZA, Nabiev AN,. [The effect of galbanic acid on the course of experimental hepatitis]. Farmakol Toksikol 1990; 53: 41-3. (Pubitemid 20101358)
16. Kim KH, Lee HJ, Jeong SJ, Lee EO, Kim HS, Zhang Y, Ryu SY, Lee MH, Lu J, Kim SH,. Galbanic acid isolated from Ferula assafoetida exerts in vivo anti-tumor activity in association with anti-angiogenesis and anti-proliferation. Pharm Res 2011; 28: 597-609.
17. Guo J, Jiang C, Wang Z, Lee HJ, Hu H, Malewicz B, Lee HJ, Lee JH, Baek NI, Jeong JH, Kim DK, Kang KS, et al. A novel class of pyranocoumarin anti-androgen receptor signaling compounds. Mol Cancer Ther 2007; 6: 907-17. (Pubitemid 46554560)
18. Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, Lee EO, Lee HJ, Lee JH, Kim MS, Kim SH, Lu J,. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res 2006; 66: 453-63. (Pubitemid 43166054)
19. Lee S, Ryu, SY, Ahn, JW,. Reinvestigation of the structure of galbanic acid by 2D NMR techniques including 2D inadequate. Bull Korean Chem 1998; 19: 384-6.
20. Hu H, Jiang C, Ip C, Rustum YM, Lu J,. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 2005; 11: 2379-88. (Pubitemid 40490199)
21. Malewicz B, Wang Z, Jiang C, Guo J, Cleary MP, Grande JP, Lu J,. Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements. Carcinogenesis 2006; 27: 1739-47. (Pubitemid 44288657)
22. Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP, Lu J,. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila) 2009; 2: 484-95.
23. Cho SD, Jiang C, Malewicz B, Dong Y, Young CY, Kang KS, Lee YS, Ip C, Lu J,. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 2004; 3: 605-11. (Pubitemid 39193739)
24. Zhang Y, Zhang J, Wang L, Quealy E, Gary BD, Reynolds RC, Piazza GA, Lu J,. A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model. Cancer Prev Res (Phila) 2010; 3: 885-95.
25. Muller H, Moroni MC, Vigo E, Petersen BO, Bartek J, Helin K,. Induction of S-phase entry by E2F transcription factors depends on their nuclear localization. Mol Cell Biol 1997; 17: 5508-20. (Pubitemid 27357647)
26. Wang F, Ezell SJ, Zhang Y, Wang W, Rayburn ER, Nadkarni DH, Murugesan S, Velu SE, Zhang R,. FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 2010; 28: 234-41.
27. Schrödinger, LLC. Maestro, version 9.0. New York, NY: Schrödinger, LLC, 2009.
28. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R,. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006; 49: 534-53. (Pubitemid 43157487)
29. Schrödinger, LLC. Glide, version 5.0. New York, NY: Schrödinger, LLC, 2009.
30. 1. Carcinogenesis 2009; 30: 818-23.
31. Wang Z, Lee HJ, Chai Y, Hu H, Wang L, Zhang Y, Jiang C, Lu J,. Persistent P21Cip1 induction mediates G(1) cell cycle arrest by methylseleninic acid in DU145 prostate cancer cells. Curr Cancer Drug Targets 2010; 10: 307-18.
32. Centenera MM, Harris JM, Tilley WD, Butler LM,. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol 2008; 22: 2373-82.
33. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C,. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 2002; 21: 4037-48. (Pubitemid 34857436)
34. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP,. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277: 26321-6. (Pubitemid 34967123)
35. Joly-Pharaboz MO, Ruffion A, Roch A, Michel-Calemard L, Andre J, Chantepie J, Nicolas B, Panaye G,. Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 2000; 73: 237-49.
36. Sherr CJ, Roberts JM,. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12. (Pubitemid 29297917)
37. De Miguel F, Lee SO, Onate SA, Gao AC,. Stat3 enhances transactivation of steroid hormone receptors. Nucl Recept 2003; 1: 3-11.
38. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q, Gao AC,. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 2010; 70: 3309-19.
39. Gioeli DG,. The promise of novel androgen receptor antagonists. Cell Cycle 2010; 9: 440-1.
40. Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML, Balk SP,. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 2006; 169: 682-96. (Pubitemid 44156324)
41. Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT,. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci USA 2006; 103: 15085-90. (Pubitemid 44583168)
42. Hunter T, Pines J,. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-82. (Pubitemid 24363801)
43. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE,. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005; 96: 251-8. (Pubitemid 41080506)
44. Lu S, Tsai SY, Tsai MJ,. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997; 57: 4511-16. (Pubitemid 27441054)
45. 1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene 2009; 28: 1016-27.
46. Yamamoto A, Hashimoto Y, Kohri K, Ogata E, Kato S, Ikeda K, Nakanishi M,. Cyclin E as a coactivator of the androgen receptor. J Cell Biol 2000; 150: 873-80.
47. Lim JT, Mansukhani M, Weinstein IB,. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci USA 2005; 102: 5156-61.
48. Taipale M JD, Lindquist S,. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-28.